Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. - Wikidata - awgldk - TriplyDB

Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.

Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.

http://www.wikidata.org/entity/Q33484071

about

ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes Clinical applications of Gallium-68 PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature Imaging of gastroenteropancreatic neuroendocrine tumors High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.Multimodal management of neuroendocrine liver metastases.Bone metastases and skeletal-related events from neuroendocrine tumors.Effects of chelator modifications on (68)Ga-labeled [Tyr (3)]octreotide conjugates.Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors.Staging of neuroendocrine tumours: comparison of [⁶⁸Ga]DOTATOC multiphase PET/CT and whole-body MRI.Metallic radionuclides in the development of diagnostic and therapeutic radiopharmaceuticals.Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances Unconventional nuclides for radiopharmaceuticals A practical guide to the construction of radiometallated bioconjugates for positron emission tomography.Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis.An Incidental Solitary Plasmacytoma of Bone Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography.Prospective of ⁶⁸Ga-radiopharmaceutical development.(68)Ga-DOTATATE positron emission tomography/computed tomography scan in the detection of bone metastases in pediatric neuroendocrine tumors PET/CT imaging of neuroendocrine tumors with (68)Gallium-labeled somatostatin analogues: An overview and single institutional experience from India.The molecular pathogenesis and management of bronchial carcinoids.Diagnosis of bone metastases: a meta-analysis comparing ¹⁸FDG PET, CT, MRI and bone scintigraphy.⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.⁶⁸Ga-labelled peptides in the management of neuroectodermal tumours.Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis.Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis.Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors The role of multimodal treatment in patients with advanced lung neuroendocrine tumors.Is ⁶⁸Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?Development of ⁶⁸Ga-labelled DTPA galactosyl human serum albumin for liver function imaging.The utility of 68Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors.Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA.The Evolution of Neuroendocrine Tumor Treatment reflected by ENETS Guidelines.Catching the Zebra: Clinical Pearls and Pitfalls for the Successful Diagnosis of Zollinger-Ellison Syndrome.CT and enhanced CT in diagnosis of gastrointestinal neuroendocrine carcinomas.Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine.

P2860

Q24603675-2BAEE39F-1050-4D6B-9BB3-F442B2D25AA1 Q26849276-D11BA302-3847-4E57-B1F4-00D96DEC9B78 Q26992201-6B3AFCBE-2609-49F3-B8C2-AD83673720B0 Q28238305-AEB082DC-EB16-4660-828B-AFA740C2E9DF Q28260008-F77262D5-7CE9-4957-980C-412F8559C574 Q33611575-48864655-8628-4CFC-862A-62BAA2234889 Q34157385-4C771AB5-37DA-4DA2-935B-295D5C2B23ED Q34248487-A48A8173-3C8E-4F95-8843-A0DF5FA274C5 Q34477028-DCEA9697-8D0E-430C-B3A0-2545FA97D5BE Q34528199-2E833F2E-3021-49E1-96EB-415D86654180 Q34850930-B8A40783-115B-4553-BA23-8A675A89D4FE Q35087810-AFE63103-54C5-4D73-82F5-385D552A2E11 Q35895493-4F96B61B-E1BA-43AA-AFAB-9A9B7E87F52D Q36661451-BF7166A0-B1F4-4207-988C-438737F37CD4 Q37026964-F77554A3-918C-4039-9320-B0B80B24F13A Q37063180-2FF6D04F-5006-4752-97CA-7BF4F37D92B9 Q37125550-9BF170C9-A039-4A49-B23A-1DE91C5D0562 Q37129181-6175861F-012F-4AC4-9CC7-05AD34867D32 Q37172093-87DDB7C1-D9CF-46E9-8773-FE6265592D71 Q37201458-350B919D-2B86-4611-9FF5-A0F92569A9F1 Q37400484-382CC379-6F08-4EA9-BBBA-5208DD6A4F3E Q37435222-6DCDA6EF-06B5-428B-9125-E7C1AEF30138 Q37592445-DFB012FD-FF88-4546-9EC4-C5A48207BE2B Q37592451-C66651C5-EA17-4D08-87EE-8EF5736B5A52 Q37833109-465473AF-1597-4544-A377-C9FFDB0A7F7E Q37925631-FE237017-D278-47C1-9528-54B2C85EB676 Q37990397-8D911BF0-CCB1-41E7-99F5-80A9917C5968 Q37990398-8C339152-66E8-49A9-8D8C-F69FD183CC6E Q38123057-DA9E83FF-B8DF-4146-90CE-025F30D7F200 Q38127505-946D7010-23D7-41D0-BA95-152E72DC5E5B Q38469898-DE899D14-617F-47A4-BEA8-F8CC0BDBF59B Q45896572-7D50F25C-5552-4B14-9DA5-C8FA73EC95CB Q46152235-D2C468D1-0ED7-4455-9171-339E69842C66 Q46566508-5D790E4D-3EFF-449C-B3EB-E57958AB0B1C Q47731752-13DF77CF-DA21-427E-A37D-3CC2476E5114 Q48089118-8F5A1B68-87AE-48A4-9921-13EEC9848CC5 Q50103017-9C9C0A33-7435-4CBF-81FB-1CEBC3685F2A Q50511434-438585AF-AD66-4247-8066-2316809329B7 Q50969115-258FD0DD-ACD6-46FA-BB43-1DD352228CDC Q51510849-BCD273CB-2057-44D7-9239-D26A3D23C7FB

P2860

Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.

http://www.wikidata.org/entity/Q33484071

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Bone metastases in patients wi ...... n to CT and bone scintigraphy.

@ast

Bone metastases in patients wi ...... n to CT and bone scintigraphy.

@en

type

label

Bone metastases in patients wi ...... n to CT and bone scintigraphy.

@ast

Bone metastases in patients wi ...... n to CT and bone scintigraphy.

@en

prefLabel

Bone metastases in patients wi ...... n to CT and bone scintigraphy.

@ast

Bone metastases in patients wi ...... n to CT and bone scintigraphy.

@en

P1433

Q33484071-7A6BFE61-B013-41DE-B722-AC147CCCD11F

P1476

Q33484071-8DABC5C2-F26E-4EEF-8892-1A897D1C2DCE

P2093

Q33484071-30309350-13AE-4AB0-9FAF-81689E8FDECA

Q33484071-5B5EADDA-BD78-427C-AD67-8115AB74A569

Q33484071-877C6767-6F25-412B-BBE8-521FDF873660

Q33484071-9647F5EE-7A14-4A97-9CD3-618A65D29DBE

Q33484071-A16E427D-76EE-4059-8F5D-899824E340FC

Q33484071-A52DC578-BB1E-418A-B111-A76C3AF61B67

Q33484071-B06172D1-6C37-4221-8546-71BE6A9D3915

P304

Q33484071-A63AD8D7-6D17-4478-92BD-646163666DCD

P31

Q33484071-084F9AC8-6F25-4B2F-AA62-B6000C4B827F

P356

Q33484071-47731A8E-E117-477C-AC47-D5C91142A47E

P407

Q33484071-11AED130-735A-4091-887E-103FBFD2EE4D

P433

Q33484071-47E87A87-2D85-47C5-97E4-6F2CA2541743

P478

Q33484071-B886317B-4DCD-4B16-865A-7AE0F03ADAA0

P50

Q33484071-372B6042-0990-49B3-968F-0BE07F0BB2B5

Q33484071-839E52DB-59DC-45AA-AF89-3333ABBC02F3

Q33484071-BB11878F-4E26-4A0F-A003-0A075D35EC6D

P577

Q33484071-1F7E5F65-794A-4C76-A575-168ED0A9BDA8

P5875

Q33484071-7FA56448-16A7-4EB0-B78F-78D7A5618002

P698

Q33484071-1793DFA3-6490-4FBD-BBB6-18B2E475E3AC

P356

JNUMED.108.060236

P1433

The Journal of Nuclear Medicine

P1476

Bone metastases in patients wi ...... on to CT and bone scintigraphy

@en

P2093

Benjamin Henninger

http://www.w3.org/2001/XMLSchema#string

Christian Uprimny

http://www.w3.org/2001/XMLSchema#string

Daniel Putzer

http://www.w3.org/2001/XMLSchema#string

Dorota Kendler

http://www.w3.org/2001/XMLSchema#string

Georg Dobrozemsky

http://www.w3.org/2001/XMLSchema#string

Irene Johanna Virgolini

http://www.w3.org/2001/XMLSchema#string

Michael Gabriel

http://www.w3.org/2001/XMLSchema#string

P304

1214-1221

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2967/JNUMED.108.060236

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P50

Clemens Decristoforo

P577

2009-07-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26681114

http://www.w3.org/2001/XMLSchema#string

P698

19617343

http://www.w3.org/2001/XMLSchema#string